rs1056234449
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 1P and 6B. PP2BP4_ModerateBS2
The NM_001387283.1(SMARCA4):c.4255C>T(p.Arg1419Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000692 in 1,444,666 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 8/12 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001387283.1 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SMARCA4 | NM_001387283.1 | c.4255C>T | p.Arg1419Cys | missense_variant | 30/36 | ENST00000646693.2 | NP_001374212.1 | |
SMARCA4 | NM_003072.5 | c.4171-1765C>T | intron_variant | ENST00000344626.10 | NP_003063.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SMARCA4 | ENST00000646693.2 | c.4255C>T | p.Arg1419Cys | missense_variant | 30/36 | NM_001387283.1 | ENSP00000495368.1 | |||
SMARCA4 | ENST00000643549.1 | c.4156C>T | p.Arg1386Cys | missense_variant | 29/35 | ENSP00000493975.1 | ||||
SMARCA4 | ENST00000344626.10 | c.4171-1765C>T | intron_variant | 1 | NM_003072.5 | ENSP00000343896.4 | ||||
SMARCA4 | ENST00000541122.6 | c.4072-1756C>T | intron_variant | 5 | ENSP00000445036.2 | |||||
SMARCA4 | ENST00000643296.1 | c.4072-1756C>T | intron_variant | ENSP00000496635.1 | ||||||
SMARCA4 | ENST00000644737.1 | c.4072-1756C>T | intron_variant | ENSP00000495548.1 | ||||||
SMARCA4 | ENST00000589677.5 | c.4072-1756C>T | intron_variant | 5 | ENSP00000464778.1 | |||||
SMARCA4 | ENST00000643995.1 | c.3583-1756C>T | intron_variant | ENSP00000496004.1 | ||||||
SMARCA4 | ENST00000644963.1 | c.2815-1756C>T | intron_variant | ENSP00000495599.1 | ||||||
SMARCA4 | ENST00000644065.1 | c.2797-1756C>T | intron_variant | ENSP00000493615.1 | ||||||
SMARCA4 | ENST00000642350.1 | c.2656-1756C>T | intron_variant | ENSP00000495355.1 | ||||||
SMARCA4 | ENST00000643857.1 | c.2524-1756C>T | intron_variant | ENSP00000494159.1 | ||||||
SMARCA4 | ENST00000538456.4 | c.328-1756C>T | intron_variant | 3 | ENSP00000495197.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 0.00000692 AC: 10AN: 1444666Hom.: 0 Cov.: 28 AF XY: 0.00000835 AC XY: 6AN XY: 718234
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 15, 2022 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Apr 14, 2021 | - - |
not provided Uncertain:1Other:1
not provided, no classification provided | phenotyping only | GenomeConnect - Invitae Patient Insights Network | - | Variant interpreted as Uncertain significance and reported on 01-03-2017 by Ambry Genetics. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Apr 14, 2021 | Not observed in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
Rhabdoid tumor predisposition syndrome 2;C3553249:Intellectual disability, autosomal dominant 16 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 25, 2022 | - - |
Rhabdoid tumor predisposition syndrome 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 18, 2023 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 1419 of the SMARCA4 protein (p.Arg1419Cys). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with SMARCA4-related conditions. ClinVar contains an entry for this variant (Variation ID: 480587). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at